Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma

International Journal of Molecular Medicine

Volumn 30, Issue 4, 2012, Pages 747-754

  Liu, Lei ^a,b,g   Wu, Wenbin ^b   Zhu, Guangze ^b,c   Liu, Liming ^b,d   Guan, Guofang ^b,e   Li, Xiao ^a,b,f   Jin, Ningyi ^b   Chi, Baorong ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c CHANGCHUN UNIVERSITY OF CHINESE MEDICINE   (China)

^d JILIN ACADEMY OF AGRICULTURAL SCIENCES   (China)

^e THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^f BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^g CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Antitumor; Apoptin; Apoptosis; Conditional replication competent adenovirus; Gastric carcinoma

Indexed keywords

APOPTIN; ONCOLYTIC ADENOVIRUS; RNA DIRECTED DNA POLYMERASE; TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; STOMACH EPITHELIUM; TUMOR GROWTH; VIRAL GENE THERAPY; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CAPSID PROTEINS; CELL LINE; CELL LINE, TUMOR; CHICKEN ANEMIA VIRUS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; STOMACH; STOMACH NEOPLASMS; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866500917     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1077     Document Type: Article

References (31)

1. Xu Y, Liu Z, Kong H, et al: Co-expression of interleukin 12 enhances antitumor effects of a novel chimeric promoter-mediated suicide gene therapy in an immunocompetent mouse model. Biochem Biophys Res Commun 412: 763-768, 2011.
2. Alemany R: Cancer selective adenoviruses. Mol Aspects Med 28: 42-58, 2007.
3. Haviv YS and Curiel DT: Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 53: 135-154, 2001. (Pubitemid 33135561)
4. Li X, Liu Y, Wen Z, et al: Potent antitumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer 9: 10, 2010.
5. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P and Fisher PB: Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 102: 14034-14039, 2005. (Pubitemid 41377698)
6. Post DE, Sandberg EM, Kyle MM, et al: Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 67: 6872-6881, 2007. (Pubitemid 47105534)
7. Kovalenko OA, Kaplunov J, Herbig U, Detoledo S, Azzam EI and Santos JH: Expression of (NES-)hTERT in cancer cells delays cell cycle progression and increases sensitivity to genotoxic stress. PLoS One 5: e10812, 2010.
8. Wojciak JM, Martinez-Yamout MA, Dyson HJ and Wright PE: Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains. EMBO J 28: 948-958, 2009.
9. Hoti N, Chowdhury WH, Mustafa S, et al: Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses. Cancer Gene Ther 17: 585-597, 2010.
10. Danen-Van Oorschot AA, Fischer DF, Grimbergen JM, et al: Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 94: 5843-5847, 1997. (Pubitemid 27241859)
11. Backendorf C, Visser AE, de Boer AG, et al: Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol 48: 143-169, 2008. (Pubitemid 351756360)
12. Schoop RA, Baatenburg de Jong RJ and Noteborn MH: Apoptin induces apoptosis in an oral cancer mouse model. Cancer Biol Ther 7: 1368-1373, 2008.
13. Los M, Panigrahi S, Rashedi I, et al: Apoptin, a tumor-selective 14. Rohn JL and Noteborn MH: The viral death effector Apoptin reveals tumor-specific processes. Apoptosis 9: 315-322, 2004.
14. Zhang YH, Leliveld SR, Kooistra K, et al: Recombinant Apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in a normal-cell-specific fashion. Exp Cell Res 289: 36-46, 2003. (Pubitemid 36993835)
15. Li X, Jin N, Mi Z, et al: Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro. Int J Cancer 119: 2948-2957, 2006. (Pubitemid 44846250)
16. Lian H, Jin N, Li X, et al: Induction of an effective antitumor immune response and tumor regression by combined administration of IL-18 and Apoptin. Cancer Immunol Immunother 56: 181-192, 2007. (Pubitemid 44833092)
17. Li Q, Zhu J, Sun F, Liu L, Liu X and Yue Y: Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3. Int J Mol Med 28: 101-108, 2011.
18. Zainal Ariffin SH, Wan Omar WH, Zainal Ariffin Z, Safian MF, SenafiS and Megat Abdul Wahab R: Intrinsic anticarcinogenic effects of Piper sarmentosum ethanolic extract on a human hepatoma cell line. Cancer Cell Int 9: 6, 2009.
19. Candal E, Anadon R, DeGrip WJ and Rodriguez-Moldes I: Patterns of cell proliferation and cell death in the developing retina and optic tectum of the brown trout. Brain Res Dev Brain Res 154: 101-119, 2005. (Pubitemid 40023135)
20. Patrascu F, Croitoru A, Gramaticu I, Andrei M, Teiutanu A and Diculescu M: Locally advanced or metastatic gastric cancer - new therapeutic solutions. Rev Med Chir Soc Med Nat Iasi 115: 20-26, 2011 (In Romanian).
21. Milne AN, Carneiro F, O'Morain C and Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 126: 615-628, 2009.
22. Wu CL, Shieh GS, Chang CC, et al: Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models. Clin Cancer Res 14: 1228-1238, 2008.
23. Kirn DH and McCormick F: Replicating viruses as selective cancer therapeutics. Mol Med Today 2: 519-527, 1996. (Pubitemid 126376968)
24. Shisler J, Duerksen-Hughes P, Hermiston TM, Wold WS and Gooding LR: Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J Virol 70: 68-77, 1996. (Pubitemid 126508770)
25. Fischer U and Schulze-Osthoff K: New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 57: 187-215, 2005. (Pubitemid 41043884)
26. Oro C and Jans DA: The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr Drug Targets 5: 179-190, 2004. (Pubitemid 38279416)
27. Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F and Tavassoli M: TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 23: 1153-1165, 2004. (Pubitemid 38269969)
28. Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb AJ and Noteborn MH: Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res 55: 486-489, 1995.
29. Noteborn MH: Proteins selectively killing tumor cells. Eur J Pharmacol 625: 165-173, 2009.
30. Pavet V, Portal MM, Moulin JC, Herbrecht R and Gronemeyer H: Towards novel paradigms for cancer therapy. Oncogene 30: 1-20, 2011.
31. Chowdhury I, Tharakan B and Bhat GK: Caspases - an update. Comp Biochem Physiol B Biochem Mol Biol 151: 10-27, 2008.